Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-lactamase enzymes are bacterial enzymes that hydrolyze and inactivate beta-lactam antibiotics, leading to antibiotic resistance. The Ambler classification system divides beta-lactamases into four classes (A–D) based on amino acid sequence homology. Ambler class A beta-lactamases are serine-based enzymes that use a conserved serine residue (Ser70) as a nucleophile to attack the carbonyl carbon of the amide bond in the β-lactam ring of antibiotics. This reaction results in cleavage of the β-lactam ring, rendering the antibiotic ineffective. Class A enzymes can hydrolyze penicillins, most cephalosporins, monobactams, and some carbapenems. Common pathogens producing class A beta-lactamases include *Klebsiella pneumoniae*, *Escherichia coli*, and *Pseudomonas aeruginosa*. Many class A beta-lactamases are inhibited by classical inhibitors such as clavulanic acid or tazobactam.
Hydrolyzes β-lactam ring of antibiotics, rendering them ineffective against penicillin-binding proteins (PBPs).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-Lactamase Ambler Class A (Class A Beta-Lactamase).